From the Boston Globe Business Team
Drug shows promise for new uses, firm says
April 18, 2007 04:02 PM
Email|
Comments (0)|
Text size
–
+
EPIX Pharmaceuticals Inc., of Lexington, today said there were positive results in cognitive development recorded from early-stage clinical trials of PRX-07034, its anti-obesity drug, which is being tested for possible use against Alzheimer’s disease and schizophrenia.
The early tests were for ascending doses and included 33 subjects in an in-patient setting. Subjects tolerated the doses and ‘‘no serious adverse events were reported,’’ according to a news release.
The results were announced at a presentation by Kimberley S. Gannon, senior director of biology for EPIX, at a conference on Alzheimer’s in the Dominican Republic.
(By Thomas C. Palmer Jr., Globe staff)
